MIAMI, July 24, 2017 /PRNewswire/ -- Longeveron LLC is sponsoring a regenerative medicine symposium at the 2017 International Association of Gerontology and Geriatrics (IAGG) World Congress on July 25 in San Francisco.
The symposium, titled Regenerative Medicine Alternatives for Aging Conditions, will feature a global panel of physicians who are experts in stem cell therapy and geriatric conditions, such as Aging Frailty and Alzheimer's disease. Longeveron's Co-founder and Chief Science Officer, Joshua M. Hare, M.D., will lead the panel, which includes Jeremy D. Walston, M.D. of Johns Hopkins University School of Medicine, Bruno Vellas, M.D., Ph.D. of Toulouse University Hospital, France, and Hidenori Arai, M.D., Ph.D., of National Center for Geriatrics and Gerontology, Japan.
According to Suzanne Liv Page, Longeveron's Chief Operating Officer, "We are honored to bring together this panel of international experts to share cutting-edge science, trial results and experiences from around the globe."
The primary objective of the symposium is to educate participants about the use of regenerative medicine therapies to study and treat various aging-related conditions. The panel will also discuss current Longeveron sponsored clinical trials to treat Aging Frailty and Alzheimer's disease, and the approval pathways in Japan, Europe and the U.S., including the 21st Century Cures Act.
Regenerative medicine therapy for aging-related conditions is emerging as one of the most promising and intensely investigated areas of clinical research and development. Longeveron is a leader in stem cell research for aging conditions. The symposium is open to all registered attendees of the IAGG World Congress. For more information on the symposium visit www.iagg2017.org/program/industry-supported-symposia
The IAGG 2017 World Congress is July 23-27, and is the world's largest conference on aging, providing a unique forum for medical and scientific researchers, clinicians and industry professionals to address issues impacting today's older population.
About Longeveron
Longeveron is a regenerative medicine therapy company founded in 2014. Longeveron's goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company's research focus areas include Alzheimer's disease, Aging Frailty and the Metabolic Syndrome. Longeveron produces LMSCs in its own state-of-the-art cGMP cell processing facility. www.longeveron.com
Contact:
Suzanne Liv Page
spage@longeveron.com
305.909.0850
SOURCE Longeveron LLC